



CASE 4 20021B/C1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL820015669US  
Express Mail Label Number

June 3, 2002  
Date of Deposit

RECEIVED  
JUN 06 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

WAGNER ET AL.

Examiner: Di Nola Baron, L.

APPLICATION NO: 09/920,159

FILED: AUGUST 1, 2001

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents  
Washington, D.C. 20231

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6807  
Date: June 3, 2002

  
Diane Tso  
Attorney for Applicants  
Reg. No. 46,012



06-04-02

CASE 4-20921B/C1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 820015669US  
Express Mail Label Number

June 3, 2002  
Date of Deposit

1614#9  
YC  
6:10  
RECEIVED  
JUN 06 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
WAGNER ET AL.

Art Unit: 1614

Examiner: Di Nola Baron, L.

APPLICATION NO: 09/920,159

FILED: AUGUST 1, 2001

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6807

  
Diane Tso  
Attorney for Applicants  
Reg. No. 46,012

Date: June 3, 2002

5-8